Lawrence S. Lamb Ph.D.
Net Worth

Last updated:

What is Lawrence S. Lamb Ph.D. net worth?

The estimated net worth of Dr. Lawrence S. Lamb Ph.D. is at least $1,322,384 as of 16 Aug 2022. He owns shares worth $227,384 as insider and has received compensation worth at least $1,095,000 in IN8bio, Inc..

What is the salary of Lawrence S. Lamb Ph.D.?

Dr. Lawrence S. Lamb Ph.D. salary is $365,000 per year as Executive Vice President, Co-Founder & Chief Scientific Officer in IN8bio, Inc..

How old is Lawrence S. Lamb Ph.D.?

Dr. Lawrence S. Lamb Ph.D. is 71 years old, born in 1954.

What stocks does Lawrence S. Lamb Ph.D. currently own?

As insider, Dr. Lawrence S. Lamb Ph.D. owns shares in one company:

Company Title Shares Price per share Total value
IN8bio, Inc. (INAB) Executive Vice President, Co-Founder & Chief Scientific Officer 99,730 $2.28 $227,384

What does IN8bio, Inc. do?

IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Lawrence S. Lamb Ph.D. insider trading

IN8bio, Inc.

Transaction Date Security Shares Price per share Total value Source
Purchase
Common Stock 526 $1.9 $999
Option
Employee Stock Option (right to buy) 26,204 $1.07 $28,012
Option
Common Stock 26,204 $1.07 $28,012

IN8bio key executives

IN8bio, Inc. executives and other stock owners filed with the SEC: